Will 'Businessman' Trump See The Value In Indian Generics?
The election of Donald Trump as the next US president might suggest a degree of policy unpredictability for pharma companies but Indian firms are hoping that the businessman in the real estate mogul and President-elect will see the value that generics offer.
You may also be interested in...
Other retailers may be feeling the pain, but India’s nascent e-pharmacy sector says business is better than ever since the country’s prime minister outlawed 86% of the cash in circulation to address tax avoidance.
South Korean analysts and pharma firms are generally viewing Donald Trump's win in the US presidential election as positive for the sector, which is stepping up efforts to enter global markets including the US.
Although Chinese President Xi Jinping has expressed the country's willingness to work with the newly elected US president to promote ties in a constructive way, potential setbacks for bilateral trade and regulatory talks are worrying observers.